Skip to content Skip to footer
Subscribe Now
Intas & Coherus
NEWS

Intas Pharmaceuticals Completes the Acquisition of Coherus BioSciences’ Udenyca (Biosimilar, Neulasta) 

Shots:  Intas Pharmaceuticals, through its Accord subsidiaries, has completed the acquisition of Coherus BioSciences’ Udenyca (pegfilgrastim-cbqv), a biosimilar of Neulasta   With the acquisition, Accord BioPharma, Intas’ U.S. specialty arm, continues Udenyca commercialization, offering patient-friendly administration options autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS)  Udenyca is a leukocyte growth factor used to reduce infection risk in…
August 6, 2025

Read more

Viewpoints_Tahi Ahmadi
VIEWPOINTS

Enhancing Capabilities: Tahi Ahmadi from Genmab in a Riveting Dialogue Exchange with PharmaShots

Shots:  Recently, Genmab acquired ProfoundBio in a strategic move to strengthen its position in the ADC space. With this acquisition, Genmab gets ProfoundBio’s novel ADC technology platforms  Today, at PharmaShots, we have Tahi Ahmadi, EVP and Chief Medical Officer at Genmab, sharing insights from the recent acquisition of ProfoundBio by Genmab  With this acquisition, Genmab…
July 29, 2024

Read more

VIEWPOINTS_Nathan McCutcheon_2023
VIEWPOINTS

Nathan McCutcheon shares highlights of Qpex Biopharma’s acquisition by Shionogi

Shots:  Nathan McCutcheon, President, and Chief Executive Officer of Shionogi, shares the highlights of the recent acquisition of Qpex Biopharma by Shionogi   Nathan believes that Qpex’s specialized expertise and extensive experience in chemistry and molecular design are sure to strengthen and be useful for the combined antibiotic pipeline   The acquisition provides Shionogi exclusive development, manufacturing,…
October 16, 2023

Read more

VIEWPOINTS_Mark Cobbold1_Carsten Linnemann2 _2023
VIEWPOINTS

Mark Cobbold and Carsten Linnemann Share Insights on Neogene Therapeutics’ Acquisition

Shots: Carsten gave the details of the agreement with Neogene Therapeutics to bring cell therapies to patients with solid tumors through Neogene’s next-generation T-cell receptor therapies. He also talked about Neogene’s TCR discovery platform Mark spoke about how this acquisition provides AstraZeneca with a unique opportunity to bring innovative science and leading experts in T-cell…
May 4, 2023

Read more

Viewpoints_Meghan Scanlon
VIEWPOINTS

PharmaShots Interview: Boston Scientific’s Meghan Scanlon Shares Insight on the Completion of its $1.07B Lumenis Acquisition

In an interview with PharmaShots, Meghan Scanlon, Senior Vice President and President for Urology and Pelvic Health at Boston Scientific shares her views on the completion of its $1.07B  acquisition of Lumenis surgical business Shots: Boston Scientific reported the closing of its acquisition of the Lumenis surgical business from a BPEA affiliate for an upfront of $1.07B. The acquisition follows the Mar…
December 20, 2021

Read more

Viewpoints_Gilles Cottier
VIEWPOINTS

PharmaShots Interview: Aceto’s Gilles Cottier Shares Insight on the Acquisition of A&C and IsleChem

In an interview with PharmaShots, Gilles Cottier, Chief Executive Officer of Aceto shared his views on the acquisitions of A&C and IsleChem to highlight the company's growth strategy. Shots: The acquisition of IsleChem has allowed the company to expand its manufacturing expertise in the US. Aceto currently has diversified access to a robust global supply chain network The acquisition…
May 11, 2021

Read more